GHK-Cu for Keloid & Scar Support

Candidate profile

People considering GHK-Cu for a keloid — a raised, firm scar that grows beyond the boundaries of the original wound and does not regress on its own. Keloids are most common on the chest, shoulders, earlobes, and back, and are more frequent in people with darker skin and a family history of keloid formation. The honest framing for this use case is not "here is how to use GHK-Cu for keloids" but "here is why the rationale is weak here and why standard-of-care treatments should lead."

Not appropriate as a substitute for dermatologic evaluation. A firm, growing, or changing skin lesion should be assessed by a clinician, both to confirm it is a keloid and to plan evidence-based treatment.

Why keloids are not an ordinary wound-healing problem

GHK-Cu (copper tripeptide-1) has a legitimate place in normal skin remodeling and wound support. It is associated with signaling that modulates the extracellular matrix, supports fibroblast activity, and helps organize collagen during healthy healing. That is the setting where its rationale is strongest.

A keloid is the opposite problem. It is a state of excessive, dysregulated collagen deposition — fibroblasts that overproduce matrix and fail to switch off. An agent that supports collagen synthesis and matrix remodeling is not obviously matched to a condition defined by too much collagen and runaway remodeling. The mechanistic story that makes GHK-Cu attractive for ordinary scars does not transfer cleanly to keloids, and may even point in an unhelpful direction. There is no controlled human evidence that GHK-Cu shrinks or prevents keloids.

What the evidence does and doesn't show

• It does not show that GHK-Cu reduces, flattens, or prevents keloid scars in controlled human studies. The interest is extrapolated from general skin-remodeling data, not from keloid trials.
• It does show, at most, a plausible role in supporting the appearance and quality of normal healing skin — a different claim entirely.
• Because keloids are driven by overactive fibroblast collagen production, a pro-remodeling peptide is a mechanistically questionable choice, not a promising one.

What standard care actually looks like

Keloid management is a well-developed area of dermatology, and these are the approaches with real evidence behind them:

• Intralesional corticosteroid injections (often triamcinolone), a first-line treatment to flatten and soften keloids.
• Silicone gel sheeting or gel, a mainstay for scar management and keloid prevention after injury or surgery.
• Pressure therapy, particularly effective for earlobe keloids after excision.
• Surgical excision combined with adjuvant radiation or steroid injection — surgery alone has a high recurrence rate, which is why it is paired with an adjunct.
• Cryotherapy, laser therapy, and other second-line options used in specific situations.

The through-line is that keloids recur easily and require a deliberate, often combination, clinical strategy. A topical peptide is not part of that established toolkit.

Realistic expectations

If someone uses GHK-Cu on or near a keloid, the realistic expectation is that it will not resolve the keloid. Any perceived improvement in surrounding skin texture should not be confused with treating the keloid itself, and relying on it can delay effective care during the window when keloids are most manageable. The most rational role for a copper peptide here is limited to general skin support, clearly separated from keloid treatment.

Safety & context

GHK-Cu is generally well tolerated topically, but that tolerability is not evidence of efficacy for keloids. The more important safety point is opportunity cost: choosing an unproven approach over interventions that work can allow a keloid to enlarge or recur. This use case exists mainly to set expectations honestly — GHK-Cu is a reasonable actor in normal skin remodeling and a poor fit for keloid scars, where dermatologist-guided standard care should lead. This overview is educational and does not constitute medical advice.